



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/076,421
Filing Date	February 19, 2002
First Named Inventor	M. WADA et al.
Group Art Unit	1614 1648
Examiner Name	IDA PARKIN
Attorney Docket Number	HAYAK 9

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					

TECH CENTER 1600/2300
NOV 04 2002
RECEIVED

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
NC	AS	WIPO	96/13160		5/9/96			
NC	AT	WIPO	02/09753A1		2/7/02			

Examiner Signature


Date Considered

03/10/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	10/076,421
Filing Date	February 19, 2002
First Named Inventor	M. WADA et al.
Group Art Unit	1614 1648
Examiner Name	IBA PARSON
Attorney Docket Number	HAYAK 9

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

RECEIVED
NOV 04 2002
TECH CENTER 1600/2900

**Examiner
Signature**

Date
Considered

03/10/04

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

AUG 15 2002

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 3600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	10/076,421		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	February 19, 2002		
		First Named Inventor	Manabu WADA et al.		
		Group Art Unit	1644/1648		
		Examiner Name	Unassigned PARICEN		
Sheet	1	of	1	Attorney Docket Number	HAYAK-9

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓		Dzung H. NGUYEN et al., "Evidence for Budding of Human Immunodeficiency Virus Type 1 Selectively From Glycolipid-Enriched Membrane Lipid Rafts," JOURNAL OF VIROLOGY, Vol. 74., No. 7, pp. 3264-3272, April 2000.	
✓		Yuri KOSHELNICK et al., "Mechanisms of Signaling Through Urokinase Receptor and The Cellular Response," THROMBOSIS and HAEMOSTASIS, 82(2), pp. 305-311, 1999.	
NC		SEKI et al., Seikagaku, 71(5), pp.350-352, 1999.	NO
✓		C. AMIEL et al., "Interleukin-16 (IL-16) Inhibits Human Immunodeficiency Virus Replication in Cells From Infected Subjects, and Serum.... THE JOURNAL OF INFECTIOUS DISEASES, Vol. 179, pp. 83-91, 1999.	
		R. PAL et al., "Inhibition of HIV-1 Infection by the β -Chemokine MDC," SCIENCE, Vol. 278, October 24, 1997.	
		J.A. LEVY et al., "Controlling HIV Pathogenesis: The Role of The Noncytotoxic Anti-HIV Response of CD8 ⁺ T Cells," IMMUNOLOGY TODAY, Vol. 17, No. 5, pp. 217-224, May 1996.	
		F. COCCHI et al., "Identification of RANTES, MIP-1 α , and MIP-1 β as the Major HIV-Suppressive Factors....," SCIENCE, Vol. 270, pp. 1811-1815, December 15, 1995.	
		B. CHEN et al., "Distinct Modes of Human Immunodeficiency Virus Type 1 Proviral Latency Revealed by Superinfection of Nonproductively....," JOURNAL OF VIROLOGY, Vol. 68, No. 2, pp. 654-660, February 1994.	
		A. FAUCI, "Host Factors and The Pathogenesis of HIV-Induced Disease," NATURE, Vol. 384, pp. 529-534, December 12, 1996.	
		Estelle OBERLIN et al., "The CXC Chemokine SDF-1 is the Ligand for LESTR/fusin and Prevents Infection by T-cell-line-adapted HIV-1," NATURE, Vol. 382, pp. 833-835, August 29, 1996.	
		M. BAIER et al., "HIV Suppression by Interleukin-16," NATURE, Vol. 378, p. 563, December 7, 1995.	
		A. ADACHI et al., "Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Non-Human Cells Transfected with an Infectious Molecular Clone," JOURNAL OF VIROLOGY, Vol. 59, No. 2, pp. 284-291, August 1988.	
✓		M. Patrizia STOPPELLI et al., "Differentiation-Enhanced Binding of the Amino-Terminal Fragment of Human Urokinase Plasminogen Activator to a Specific Receptor on U937 Monocytes," PROC. NATL. ACAD. SCI. USA, Vol. 82, pp. 4939-4943, August 1985.	

JAPANESE; NO
ENGLISH
TRANSLATION

Examiner Signature		Date Considered	03/10/04
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.